

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: MOORE et al.

Attorney Docket No.: PZ032P1C3

Application Serial No.: to be assigned

Art Unit: To be assigned

Filed: Herewith (January 25, 2002)

Examiner: To be assigned

Title: 49 Human Secreted Proteins

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir :

Prior to the prosecution of the above-captioned application, please enter the following amendments Applicants submit concurrently herewith a copy of the Petition of Extension of Time Under 37 C.F.R. §1.136 ("Petition") filed in connection with the parent Application No. 09/904,615, which extends the time from December 27, 2001, to and including January 27, 2002. This Petition evidences copendency between parent Application No. 09/904,615 and the present application.

Amendments

In the Specification

Please replace the first paragraph on page 1 with the following rewritten paragraph:

-- This application is a continuation application of U.S. Application No. 09/904,615, filed July 16, 2001, which is a continuation of U.S. Application No. 09/739,254, filed December 19, 2000 which is a continuation of 09/511,554, filed February 23, 2000, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending International patent application Serial No. PCT/US99/19330, filed August 24, 1999, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application Numbers 60/097,917, filed August 25, 1998 and 60/098,634 filed August 31, 1998. --

In the Claims

Please amend claim 17 as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

Please add the following claim:

-- 24. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1. --

REMARKS

The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425.

Respectfully submitted

Date: JANUARY 25, 2002


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (telephone)

KKH/JMM/CEW/mlm

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: MOORE et al.

Attorney Docket No.: PZ032P1C3

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: January 25, 2002

Examiner: To be assigned

Title: 49 Human Secreted Proteins

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

On page 1, the first paragraph has been changed as follows:

This application is a continuation application of U.S. Application No. 09/904,615, filed July 16, 2001, which is a continuation of U.S. Application No. 09/739,254, filed December 19, 2000 which is a continuation of 09/511,554, filed February 23, 2000, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending [United States patent application Serial No. PCT/US99/17130 filed July 29, 1999,] International patent Application Serial No. PCT/US99/19330, filed August 24, 1999, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application Numbers 60/097,917, filed August 25, 1998 and 60/098,634 filed August 31, 1998, each of which are hereby incorporated by reference.

In the Claims:

Claim 17 has been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 [or the polynucleotide of claim 1].